181 related articles for article (PubMed ID: 36643801)
1. Low-density lipoprotein cholesterol goal attainment in Germany: Results from the DA VINCI study.
Gouni-Berthold I; Schaper F; Schatz U; Tabbert-Zitzler A; Fraass U; Sauer S; Ray KK
Atheroscler Plus; 2022 Dec; 50():10-16. PubMed ID: 36643801
[TBL] [Abstract][Full Text] [Related]
2. Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? : Results from the DA VINCI study.
Siostrzonek P; Brath H; Zweiker R; Drexel H; Hoelzl R; Hemetsberger M; Ray KK
Wien Klin Wochenschr; 2022 Apr; 134(7-8):294-301. PubMed ID: 34870742
[TBL] [Abstract][Full Text] [Related]
3. The DA VINCI study: is Ireland achieving ESC/EAS guideline-directed LDL-C goals?
Offiah G; O'Connor C; Kennedy C; Gallagher J; O'Connor P; McAdam B; Ray KK; Schoonen M; Maher V
Ir J Med Sci; 2023 Jun; 192(3):1077-1084. PubMed ID: 35776266
[TBL] [Abstract][Full Text] [Related]
4. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study.
Ray KK; Molemans B; Schoonen WM; Giovas P; Bray S; Kiru G; Murphy J; Banach M; De Servi S; Gaita D; Gouni-Berthold I; Hovingh GK; Jozwiak JJ; Jukema JW; Kiss RG; Kownator S; Iversen HK; Maher V; Masana L; Parkhomenko A; Peeters A; Clifford P; Raslova K; Siostrzonek P; Romeo S; Tousoulis D; Vlachopoulos C; Vrablik M; Catapano AL; Poulter NR;
Eur J Prev Cardiol; 2021 Sep; 28(11):1279-1289. PubMed ID: 33580789
[TBL] [Abstract][Full Text] [Related]
5. Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study.
van de Borne P; Peeters A; Janssens L; Leone A; Lemmens R; Verhaegen A; De Meulemeester M; Balthazar Y; Heijmans S; Calozet Y; Paquot N; Carlier S; Hemelsoet D; Bray S; Ray KK
Acta Cardiol; 2024 Feb; 79(1):20-29. PubMed ID: 35442151
[TBL] [Abstract][Full Text] [Related]
6. Use of combination therapy is associated with improved LDL-cholesterol management: 1-year follow-up results from the European observational SANTORINI study.
Ray KK; Aguiar C; Arca M; Connolly DL; Eriksson M; Ferrières J; Laufs U; Mostaza JM; Nanchen D; Bardet A; Lamparter M; Chhabra R; Soronen J; Rietzschel E; Strandberg T; Toplak H; Visseren FLJ; Catapano AL
Eur J Prev Cardiol; 2024 Jun; ():. PubMed ID: 38861400
[TBL] [Abstract][Full Text] [Related]
7. Optimal implementation of the 2019 ESC/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study.
Brandts J; Bray S; Villa G; Catapano AL; Poulter NR; Vallejo-Vaz AJ; Ray KK;
Lancet Reg Health Eur; 2023 Aug; 31():100665. PubMed ID: 37547279
[TBL] [Abstract][Full Text] [Related]
8. Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study.
Vrablik M; Seifert B; Parkhomenko A; Banach M; Jóźwiak JJ; Kiss RG; Gaita D; Rašlová K; Zachlederova M; Bray S; Ray KK
Atherosclerosis; 2021 Oct; 334():66-75. PubMed ID: 34482090
[TBL] [Abstract][Full Text] [Related]
9. Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study.
Allahyari A; Jernberg T; Hagström E; Leosdottir M; Lundman P; Ueda P
Eur Heart J; 2020 Oct; 41(40):3900-3909. PubMed ID: 32072178
[TBL] [Abstract][Full Text] [Related]
10. European Physician Survey Characterizing the Clinical Pathway and Treatment Patterns of Patients Post-Myocardial Infarction.
Qureshi N; Antoniou S; Cornel JH; Schiele F; Perrone-Filardi P; Brachmann J; Sidelnikov E; Villa G; Ferguson S; Rowlands C; González-Juanatey JR
Adv Ther; 2023 Jan; 40(1):233-251. PubMed ID: 36289145
[TBL] [Abstract][Full Text] [Related]
11. Implications of ACC/AHA Versus ESC/EAS LDL-C Recommendations for Residual Risk Reduction in ASCVD: A Simulation Study From DA VINCI.
Vallejo-Vaz AJ; Bray S; Villa G; Brandts J; Kiru G; Murphy J; Banach M; De Servi S; Gaita D; Gouni-Berthold I; Kees Hovingh G; Jozwiak JJ; Jukema JW; Gabor Kiss R; Kownator S; Iversen HK; Maher V; Masana L; Parkhomenko A; Peeters A; Clifford P; Raslova K; Siostrzonek P; Romeo S; Tousoulis D; Vlachopoulos C; Vrablik M; Catapano AL; Poulter NR; Ray KK;
Cardiovasc Drugs Ther; 2023 Oct; 37(5):941-953. PubMed ID: 35567726
[TBL] [Abstract][Full Text] [Related]
12. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
[TBL] [Abstract][Full Text] [Related]
13. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic.
Barkas F; Milionis H; Kostapanos MS; Mikhailidis DP; Elisaf M; Liberopoulos E
Curr Med Res Opin; 2015 Feb; 31(2):221-8. PubMed ID: 25418708
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Low-Density Lipoprotein Cholesterol (LDL-C) Goal Achievement and Lipid-Lowering Therapy in the Patients With Coronary Artery Disease With Different Renal Functions.
Zhang S; Li ZF; Shi HW; Zhang WJ; Sui YG; Li JJ; Dou KF; Qian J; Wu NQ
Front Cardiovasc Med; 2022; 9():859567. PubMed ID: 35620524
[TBL] [Abstract][Full Text] [Related]
15. Implementation of risk-based lipid-lowering therapies in older (age ≥ 65 years) and very-old adults (age ≥ 75 years) with ischemic heart disease in the greater Salzburg region.
Kopp K; Motloch LJ; Wernly B; Berezin AE; Maringgele V; Dieplinger A; Hoppe UC; Lichtenauer M
Front Pharmacol; 2024; 15():1357334. PubMed ID: 38966548
[No Abstract] [Full Text] [Related]
16. Evaluation of Low-density Lipoprotein Cholesterol Target Attainment Rates According to the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society Dyslipidemia Guidelines for Secondary Prevention in Patients with Acute Myocardial Infarction.
Şimşek B; İnan D; Çınar T; Cagdas-Yumurtaş A; Ozan-Tanık V; Zeren G; İlker-Avcı İ; Yücel-Karabay C; Güngör B; Tokgozoğlu L
Rev Invest Clin; 2021 Nov; 73(3):371-378. PubMed ID: 34098569
[TBL] [Abstract][Full Text] [Related]
17. Guideline LDL-C Threshold Achievement in Acute Myocardial Infarction Patients: A Real-World Evidence Study Demonstrating the Impact of Treatment Intensification with PCSK9i.
Mackinnon ES; Har B; Champsi S; Wani RJ; Geyer L; Shaw E; Farris MS; Anderson TJ
Cardiol Ther; 2023 Jun; 12(2):327-338. PubMed ID: 36656500
[TBL] [Abstract][Full Text] [Related]
18. [ECS guidelines 2016 - dyslipidaemias].
Sinning D; Landmesser U
Herz; 2016 Dec; 41(8):671-676. PubMed ID: 27844136
[TBL] [Abstract][Full Text] [Related]
19. Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registry.
De Luca L; Arca M; Temporelli PL; Meessen J; Riccio C; Bonomo P; Colavita AR; Gabrielli D; Gulizia MM; Colivicchi F;
Int J Cardiol; 2020 Oct; 316():229-235. PubMed ID: 32470532
[TBL] [Abstract][Full Text] [Related]
20. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
